Back to Results
First PageMeta Content
Organic chemistry / Cabergoline / Pergolide / Next Magazine / Bromocriptine / Dopamine agonists / Lysergamides / Chemistry


U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may
Add to Reading List

Open Document

File Size: 80,83 KB

Share Result on Facebook

Company

Associated Press / The New England Journal / FDA Press / National Public Radio / /

Continent

Europe / /

Event

Product Recall / Conference Call / Product Issues / FDA Phase / /

Facility

Robert Temple / FDA Center / Dr. Temple / /

IndustryTerm

therapies for patients with Parkinson’s disease / therapies for Parkinson’s disease / treatment of Parkinson’s disease / media conference call / touchtone telephone keypad / credential media / speaker equipment / /

MedicalCondition

tricuspid regurgitation / movement disorders / Parkinson’s disease / /

Organization

U.S. Food and Drug Administration / FDA Center for Drug Evaluation and Research / Press Office / Division of Neurology Products / FDA’s office of Public Affairs / /

Person

Randall Schmidt / Sandy Walsh / Eli Lily / Joan Silverman / Susan Cruzan / John Seeney / /

/

Position

pm CT Coordinator / Coordinator / Director / speaker / Conference Leader / Medical Officer / /

Product

drug / Permax / Cabergoline / Voluntary / /

ProvinceOrState

Indiana / /

PublishedMedium

The New England Journal of Medicine / the New England Journal / /

SocialTag